company background image
0JDK logo

Iovance Biotherapeutics LSE:0JDK Stock Report

Last Price

US$3.79

Market Cap

US$1.2b

7D

-12.1%

1Y

-75.3%

Updated

09 Mar, 2025

Data

Company Financials +

Iovance Biotherapeutics, Inc.

LSE:0JDK Stock Report

Market Cap: US$1.2b

0JDK Stock Overview

A commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. More details

0JDK fundamental analysis
Snowflake Score
Valuation4/6
Future Growth5/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

My Notes

Capture your thoughts, links and company narrative

Iovance Biotherapeutics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Iovance Biotherapeutics
Historical stock prices
Current Share PriceUS$3.79
52 Week HighUS$15.89
52 Week LowUS$3.59
Beta0.93
1 Month Change-33.52%
3 Month Change-57.94%
1 Year Change-75.33%
3 Year Change-70.74%
5 Year Change-84.06%
Change since IPO-72.34%

Recent News & Updates

Recent updates

Shareholder Returns

0JDKGB BiotechsGB Market
7D-12.1%-1.3%-1.4%
1Y-75.3%-11.8%9.7%

Return vs Industry: 0JDK underperformed the UK Biotechs industry which returned -11.8% over the past year.

Return vs Market: 0JDK underperformed the UK Market which returned 9.7% over the past year.

Price Volatility

Is 0JDK's price volatile compared to industry and market?
0JDK volatility
0JDK Average Weekly Movement9.9%
Biotechs Industry Average Movement7.8%
Market Average Movement4.7%
10% most volatile stocks in GB Market10.1%
10% least volatile stocks in GB Market2.7%

Stable Share Price: 0JDK's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: 0JDK's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of UK stocks.

About the Company

FoundedEmployeesCEOWebsite
2007838Frederick Vogtwww.iovance.com

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers.

Iovance Biotherapeutics, Inc. Fundamentals Summary

How do Iovance Biotherapeutics's earnings and revenue compare to its market cap?
0JDK fundamental statistics
Market capUS$1.23b
Earnings (TTM)-US$372.18m
Revenue (TTM)US$164.07m

7.5x

P/S Ratio

-3.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0JDK income statement (TTM)
RevenueUS$164.07m
Cost of RevenueUS$124.00m
Gross ProfitUS$40.08m
Other ExpensesUS$412.25m
Earnings-US$372.18m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.14
Gross Margin24.43%
Net Profit Margin-226.84%
Debt/Equity Ratio0.1%

How did 0JDK perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/09 16:22
End of Day Share Price 2025/03/07 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Iovance Biotherapeutics, Inc. is covered by 21 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
Madhu KumarBaird
Peter LawsonBarclays